Human Type IV Collagen Biosynthesis for Scalable Cell Adhesion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing methods for producing collagen, such as acid-hydrolysis, alkali-hydrolysis, or enzymatic-hydrolysis, result in collagen derivatives that lose biological activity, have poor water solubility, and pose risks of viral infection and sensitization, while conventional recombinant expression methods are costly and not suitable for large-scale production.

Innovation Solution

A recombinant collagen is produced through genetic engineering, comprising specific amino acid sequences (SEQ ID NO: 1, 28) or variants, expressed in Escherichia coli, and purified using Ni column and strong anion exchange chromatography, suitable for large-scale production.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If traditional acid-hydrolysis, alkali-hydrolysis, or enzymatic-hydrolysis methods are used to produce collagen, then collagen derivatives can be extracted from animal tissues, but the collagen loses biological activity, has poor water solubility, and poses risks of viral infection and sensitization

Engineering Contradiction:

Improvecollagen extraction yieldVSAvoidbiological activity and safety

Core Design Contradiction:

Quantity of substanceVSReliability

Solution Approach 1:

The patent uses recombinant DNA technology to create a synthetic copy of human type IV collagen in E. coli bacteria. The collagen gene is inserted into an expression vector and transformed into E. coli, which then produces human collagen sequences that are identical to natural human collagen, avoiding the need to extract from animal tissues and eliminating risks of viral infection and sensitization while maintaining full biological activity

Inventive Principle:

Principle #26Copying

Solution Approach 2:

The patent replaces the mechanical/chemical extraction processes (acid-hydrolysis, alkali-hydrolysis, enzymatic-hydrolysis) with a biological production system. Instead of breaking down animal tissues through harsh chemical treatments, the system uses genetically engineered E. coli to biosynthesize human collagen through natural cellular processes, substituting chemical-mechanical extraction with biological synthesis

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

2Reliability

If conventional recombinant expression methods are used to produce human collagen, then biological activity is maintained, but the production is costly and not suitable for large-scale production

Engineering Contradiction:

Improvebiological activityVSAvoidproduction cost and scalability

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent utilizes E. coli bacteria as a inexpensive, easily cultivable host system for collagen production. E. coli can be grown rapidly in simple media at low cost compared to mammalian cell cultures, and the bacteria can be disposed of after use, eliminating the need for expensive facility maintenance and sterilization infrastructure required for traditional recombinant expression systems

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Solution Approach 2:

The patent optimizes several parameters to enable large-scale production: using a strong promoter (T7 promoter) to maximize expression levels, selecting E. coli strains with improved protein production capabilities, optimizing induction conditions (temperature, IPTG concentration, time), and implementing scalable fermentation protocols that can transition from laboratory to industrial production while maintaining cost-effectiveness

Inventive Principle:

Principle #35Parameter changes

3Productivity

If recombinant collagen is produced in E. coli with optimized expression, then yields and purity are improved, but complex purification steps are required

Engineering Contradiction:

Improvecollagen yieldVSAvoidpurification process complexity

Core Design Contradiction:

ProductivityVSDevice complexity

Solution Approach 1:

The patent employs a polyhistidine tag (His-tag) as an intermediary element attached to the recombinant collagen protein. This tag serves as a recognition site for nickel-affinity chromatography resin, enabling selective binding and purification of the collagen-His complex from the bacterial lysate. The His-tag acts as a molecular handle that simplifies the purification process by providing a specific, high-affinity interaction between the protein and the chromatography medium, allowing rapid separation from other bacterial proteins

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The recombinant collagen exhibits higher yields, purity, and cell adhesion activity, overcoming the limitations of traditional methods and enabling large-scale production with enhanced biological functionality.

Implementation Method 1

purified using Ni column and strong anion exchange chromatography

Methodology Applied

Scientific EffectChromatography: Chromatography

Data Source

PatentUS20250263465A1Method for preparing biosynthetic human structural material type iv collagen

Publication Date: 2025.08.21 SHANXI JINBO BIO PHARMACEUTICAL CO LTD

AI summary

Provided herein is a method of biosynthesizing human body structural material type IV collagen. Provided herein is a recombinant collagen including the sequence represented by SEQ ID NO: 1, etc. The recombinant collagen of the present application exhibits excellent cell-adhesion activity. The method of the present application utilizes genetic engineering techniques to produce the recombinant collagen, thereby overcoming the drawbacks of the prior art.